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For decades, Aggregatibacter actinomycetemcomitans has been associated with aggressive forms of period-
ontitis in adolescents. In the middle of the 1990s, a specific JP2 clone of A. actinomycetemcomitans, belonging
to the cluster of serotype b strains of A. actinomycetemcomitans and having a number of other characteristics,
was found to be strongly associated with aggressive forms of periodontitis, particularly in North Africa.
Although several longitudinal studies still point to the bacterial species, A. actinomycetemcomitans as a risk
factor of aggressive periodontitis, it is now also widely accepted that the highly leukotoxic JP2 clone of
A. actinomycetemcomitans is implicated in rapidly progressing forms of aggressive periodontitis. The JP2 clone
strainsarehighlyprevalent inhumanpopulationslivinginNorthernandWesternpartsofAfrica. Thesestrains
are also prevalent in geographically widespread populations that have originated from the Northwest Africa.
Only sporadic signs of a dissemination of the JP2 clone strains to non-African populations have been found
despite Africanslivinggeographicallywidespreadforhundredsofyears.It remains anunansweredquestionif a
particular host tropism exists as a possible explanation for the frequent colonization of the Northwest African
population with the JP2 clone. Two exotoxins of A. actinomycetemcomitans are known, leukotoxin (LtxA) and
cytolethal distending toxin (Cdt). LtxA is able to kill human immune cells, and Cdt can block cell cycle
progressionineukaryoticcellsandthusinduce cellcyclearrest.Whereastheleukotoxinproductionisenhanced
in JP2 clone strains thus increasing the virulence potential of A. actinomycetemcomitans, it has not been
possible so far to demonstrate such a role for Cdt. Lines of evidence have led to the understanding of the highly
leukotoxicJP2cloneofA. actinomycetemcomitans asanaetiologicalfactorof aggressiveperiodontitis.Patients,
who are colonized with the JP2 clone, are likely to share this clone with several family members because the
clone is transmitted through close contacts. This is a challenge to the clinicians. The patients need intense
monitoring of their periodontal status as the risk for developing severely progressing periodontal lesions are
relatively high. Furthermore, timely periodontal treatment, in some cases including periodontal surgery
supplemented by the use of antibiotics, is warranted. Preferably, periodontal attachment loss should be
prevented by early detection of the JP2 clone of A. actinomycetemcomitans bymicrobial diagnostic testing and/
or by preventive means.
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F
or decades, particular attention has been given
to the oral bacterium, Aggregatibacter actinomy-
cetemcomitans as a species implicated in the
aetiology of periodontitis among the young (15). In
addition to an exotoxin of A. actinomycetemcomitans,
called cytolethal distending toxin (Cdt) (6), one of
the major and intensely studied virulence factors of
A. actinomycetemcomitans is the leukotoxin which is
able to affect, impair the function, and kill important
cells of the human immune system (612). Although
much research has already focused on the structure,
function, secretion, and the role of the leukotoxin (6,
1222), researchers still pay attention to this important
area of research.
Population genetic analysis, as a tool to study the
population structure of A. actinomycetemcomitans, has
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evolutionary lineages corresponding to serotypes (2326).
The highly leukotoxic clone, which is termed the JP2
clone and which belongs to the group of serotype b
strains, was described in the middle of the 1990s (27).
That was shortly after the presence of a 530-basepair (bp)
deletion was demonstrated in the promoter region of the
leukotoxin gene operon in A. actinomycetemcomitans
strains with an enhanced leukotoxic activity (28). The
JP2 clone, with an estimated origin more than 2000 years
ago (29), is highly conserved based on analyses of a
collection of JP2 clone strains that were collected through
more than 20 years from individuals of diverse origin and
living geographically widespread (29). Despite the de-
monstration of minor evolutionary changes within the
genome of JP2 clone strains, these strains constitute a
unique clonal type, the characteristics of which among
other findings include the 530-bp deletion in the leuko-
toxin operon most likely implicated in the enhanced
leukotoxic activity (2831).
The JP2 clone of A. actinomycetemcomitans is ende-
mically present in Northwest Africa and particularly
associated with Northwest African populations (27, 29,
30, 3234). Furthermore, it appears to play a prominent
role in the initiation of periodontal attachment loss
among Northwest African adolescents compared with
other non-JP2 genotypes of the species (3335). As
demonstrated in prospective cohort studies in Morocco
and Ghana, the presence of the JP2 clone in dental
plaque confers a markedly increased risk for the devel-
opment of aggressive periodontitis (33, 35). This suggests
that the JP2 clone is an important aetiological agent in
aggressive periodontitis among the young.
The aim of this report is to review the latest findings
concerning the characteristics, pathogenic mechanisms,
geographic dissemination, and the role of the JP2 clone of
A. actinomycetemcomitans in aggressive periodontitis
among adolescents.
Differences in the occurrence of periodontitis
in adolescent populations living worldwide
Prevalence estimates of periodontal attachment loss in
adolescent populations from geographically widespread
parts of the world are difficult to compare, and part of
thesedifferencesmaybeduetodifferencesinstudydesigns
and diagnostic criteria (3641). However, prevalence
differences cannot be ascribed entirely to variations in
study design and diagnostic criteria. Periodontitis among
the young occurs relatively frequently in some countries,
for example, Uganda, Morocco, Ghana, Sudan, Israel,
and certain groups in Brazil and the United States (32, 35,
4247),whereasitisararediseasewithaprevalenceofless
than 1% in many other parts of the world, for example,
Northern Europe (3739, 41, 48, 49).
Studies on the epidemiology of periodontitis carried
out in the United States and in other countries with an
ethnically mixed population for decades, for example,
the United Kingdom, have often subdivided the study
population into subgroups according to ethnicity. The
overall findings in such studies have often been that
black populations are more likely to have periodontitis
than white populations (37, 38, 50, 51). It is also generally
accepted that the total periodontal disease burden in
Africa is high. For example, periodontal attachment
loss was found in 107 (21.4%) individuals out of 500
participants (mean age 13.2 years) in a recent study
undertaken in the Ghanaian adolescent population (34),
and 16.3% out of 1200 Sudanese students (mean age
15.9 years) had at least one tooth with 4 mm attachment
loss or more (47). Hence, these findings are consistent
with conclusions in other previous epidemiological studies
carried out in African countries, for example, Uganda
and Nigeria (52, 53). However, human populations show
many differences with regard to several parameters:
ethnicity (genetic profile), knowledge regarding oral and
general health, dietary habits, oral hygiene practices, other
behavioural traits, socioeconomic status, access to dental
health care services, and the microbial composition of
the dental plaque (6, 39, 41, 54, 55). All of these factors
could result in different levels and patterns of disease both
within and outside of the African continent.
In recent years, after the reporting of a high preva-
lence of the highly leukotoxic JP2 clone strains of
A. actinomycetemcomitans in Northwest African coun-
tries, it has become more and more clear that this part of
the African continent has a relatively high prevalence of
severe forms of periodontitis among the young (3135).
However, the complete picture of the geographic dis-
semination of the JP2 clone and the manifestation of the
JP2 clone-associated periodontitis is not fully elucidated.
In a very recent epidemiological study carried out in the
Eastern part of Africa, JP2 clone-positive Sudanese
adolescents were not found (47). In addition, some
A. actinomycetemcomitans strains from periodontitis
patients living in Somalia, Tanzania, and Kenya, sub-
typed according to the non-JP2 or the JP2 leukotoxin
promoter genotypes, did not belong to the group of JP2
clone strains of A. actinomycetemcomitans (30). Thus,
there are patients with aggressive periodontitis around
the world, and also in Africa, where the JP2 clone is not
necessarily implicated as an aetiological factor of the
disease. Thus, the JP2 clone of A. actinomycetemcomitans
is not the only factor involved in and cannot explain all
cases of aggressive periodontitis in the adolescent popu-
lation. More research on the pathogenesis and aetiology
of periodontal disease among the young is still needed.
Surprisingly, a more extensive spreading of the JP2
clone around the world than initially assumed seems to
have occurred (56, 57). Although the JP2 clone-associated
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understanding of the aetiology and the pathogenesis of
periodontitis among the young, the JP2 clone-associated
periodontitis is a clinical manifestation of periodontal
disease that needs intensive attention by the researchers
and clinicians. Due to the highly progressive nature and
thus the aggressive type of periodontitis linked to the
presence of the JP2 clone of A. actinomycetemcomitans,
there are many reasons to increase our understanding of
the epidemiology and treatment of this disease.
The association between the presence of the
JP2 clone of A. actinomycetemcomitans and
periodontal disease
Pioneering studies from the middle of the 1990s in-
dicated that highly leukotoxic JP2 clone strains of
A. actinomycetemcomitans were closely associated with
aggressive periodontitis (27, 30, 43, 5860). Moreover,
some early studies on the geographic dissemination of
the JP2 clone of A. actinomycetemcomitans indicated that
colonization with this clone appeared to be particu-
larly linked to aggressive periodontitis in individuals of
North African descent (27, 30). An updated list of studies
that have aimed at elucidating various aspects concerning
characteristics, function, occurrence, geographic dissem-
ination, and the role of the JP2 clone in periodontitis
is presented in Table 1 (original version of Table 1,
see Ref. 31). The majority of studies that have included
JP2 clone strains are either experimental studies, studies
based on patient groups with various periodontal disease
profiles, or cross-sectional studies. Some studies are based
on previously collected A. actinomycetemcomitans isolates
kept as a part of microbial culture collections at various
microbiological laboratories. A weakness in such studies
can be the selection of the bacterial isolates, the represen-
tativity, and that there may be a lack of detailed informa-
tion on the periodontal condition of the patients from
whom the dental plaque sampleswere originally collected.
Few longitudinal studies on the association between
thepresenceofthe JP2 clone of A. actinomycetemcomitans
and periodontal disease are available, and some of these
do not have a clear follow-up time or do include both
periodontally healthy and diseased subjects at baseline
(43, 81). That makes it impossible to determine the
temporal relationship between the colonization with
the JP2 clone and the development of periodontitis.
In addition, the number of individuals included in those
longitudinal studies was limited, thus resulting in risk
estimates with wide confidence intervals (43, 81).
To address the question concerning the temporal relation-
ship between the colonization with the JP2 clone of
A.actinomycetemcomitansandthedevelopmentofperiod-
ontal attachment loss in adolescents, more recent long-
itudinal studies with improved study design have been
published (33, 35).
The first longitudinal study on JP2 clone-associated
aggressive periodontitis, conducted in an African country,
was cross-sectional and based on a group of 301
Moroccan adolescents in Rabat, Morocco (32). That
study clearly demonstrated a strong association between
thepresenceofthe JP2 clone of A. actinomycetemcomitans
and periodontal attachment loss in Moroccan adolescents
(32). In further support of the role of the JP2 clone in
periodontal disease, diseased individuals, who were posi-
tive for the JP2 clone, had more extensive periodontal
attachment loss than those without detectable levels of the
JP2 clone (82). Furthermore, a 2-year follow-up examina-
tion of this Moroccan population showed that the
presence of the JP2 clone of A. actinomycetemcomitans
was strongly associated with the progression of perio-
dontal attachment loss (81). To elucidate the causal role of
the JP2 clone of A. actinomycetemcomitans in disease,
information on the temporal relation between the coloni-
zation and the disease is important. The first study, car-
ried out in Morocco, provided no possibility for studying
the temporal relation between the presenceofthe JP2clone
and the initiation of disease because only four period-
ontally healthy carriers were present at baseline (32).
However, a good infrastructure and some general informa-
tion obtained on periodontal diseases among adolescents
in Morocco during the first Moroccan population-based
cohort study provided an excellent platform for designing
another longitudinal study in Morocco that could focus
on the temporal relation between colonization with A.
actinomycetemcomitans and the initiation of disease. Thus,
taking the alreadyobtained experiences, results, and know-
ledge on aggressive periodontitis in Moroccan adoles-
cents into account, another prospective cohort study was
designed (33). In that second, prospective cohort study,
a screening at baseline of 700 Moroccan school children
(mean age 12.5 years) revealed that only 18 (2.6%) were
periodontally diseased (33). Thus, a total of 682 indivi-
duals provided the basis for the second longitudinal study
performed in the Moroccan population of which 428
(62.8%) returned for the 2-year follow-up. The results
showed a strong association between the presence of the
JP2 clone of A. actinomycetemcomitans and the develop-
ment of aggressive periodontitis among the Moroccan
adolescents (RR18.0; 95% CI [7.8, 41.2]). Exclusion of
the individuals, who had received antibiotics less than
3 months before examination or had received any type
of periodontal treatment since baseline, did not change
the estimates (33). Furthermore, that second prospective
Moroccan cohort study provided some evidence, although
less pronounced, that the non-JP2 genotypes of A. actinomy-
cetemcomitans are also associated with aggressive period-
ontitis in adolescents (RR3.0; 95% CI [1.3, 7.12]) (33).
This association had not been clear in the first Moroccan
cohort study where no power calculation was carried
out before the initiation of the study (32). Non-JP2
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research reports
References
Number of subjects
in the study Country of residence
Number of subjects
positive for JP2
clone strains
Geographical origin
of subjects positive
for the JP2 clone
Poulsen et al. (23)  60 Northern Europe 0 
Brogan et al. (28) 17
a Not reported 3 Not reported
Haubek et al. (24) 88 Finland 0 
Haubek et al. (27) 17 Denmark and Sweden 11 Moroccan (3), Algerian (2), the
Cape Verde islands (6)
Zambon et al. (59) 256
b USA 61 Not reported
Haubek et al. (30) 326 Geographically
widespread on five
continents
38 Moroccan (7), Algerian (2),
Ghanaian (1), from the Cape
Verde Islands (6), Brazilian (4),
Israeli (1), AfricanAmerican (17)
Tinoco et al. (61) 36 Brazil 5 Brazilian (5)
Saarela et al. (62) 163 Finland and USA 3 AfricanAmerican (2),
American (1)
Bueno et al. (43) 58 USA 8 AfricanAmerican (8)
Macheleidt et al. (63) 238 Germany 1 Ghanaian (1)
Mombelli et al. (64) 185 China 0 
He et al. (65) 43 Japan 0 
Contreras et al. (66) 94 USA 12 AfricanAmerican (2), Hispanic
(1), Jamaican (9), Asian (0),
Caucasian (0)
Haraszthy et al. (60) 146 USA 41 AfricanAmerican (33),
Caucasian (1), Hispanic (7),
AsianAmerican (0)
Tan et al. (67) 92 China 0 
Haubek et al. (32) 217 Morocco 19 Moroccan (19)
Mu ¨ller et al. (68) 97 Germany 0 
Saddi-Ortega et al. (69) 35
c Brazil 6 Brazilian (6)
Kaplan et al. (25) 33
a USA 8 African or AfricanAmerican (8)
Cortelli et al. (70) 136 Brazil 11 Brazilian (11)
Cortelli et al. (71) 203 Brazil 13 Brazilian (13)
Leung et al. (72) 56 China 0 
Orru et al. (56) 81 Italia (Sardinia) 6 Not reported
Junior et al. (73) 40 Brazil 2 Not reported
Haubek et al. (29) 82 Geographically
widespread on five
continents
66 Moroccan (28), Algerian (2),
Ghanaian (1), from the Cape
Verde Islands (6), Brazilian (4),
Israeli (3), Turkish (1), from the
Mediterranean area (2),
Portuguese (1), AfricanAmerican
(16), unknown (2)
Fine et al. (74) 1075 USA 7 AfricanAmerican (6), Hispanic (1)
Van der Reijden et al. (75) 107 Indonesia 0 
Haubek et al. (33) 700 Morocco 95 Moroccan (95)
Viera et al. (76) 86
d Brazil 0 
Sakellari et al. (77) 228 Greece 0 
A ˚ berg et al. (34) 500 Ghana 44 Ghanaian (44)
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ciated with the development of periodontal attachment
loss are in concordance with results from other long-
itudinal studies performed in Indonesia (JAVA-project)
and in the United States (74, 83, 84). The discrepancy
in the conclusions concerning the role of the non-JP2
genotypes of A. actinomycetemcomitans between the first
and the second Moroccan cohort study can be explained
by a number of factors, for example, the disease status
at baseline and the sample size of the study populations.
Thus, the second longitudinal study, performed in the
Moroccan population, showed evidence of A. actinomy-
cetemcomitans as a risk factor for the initiation of perio-
dontal attachment loss, but is also the first evidence of
a strong association particularly between the presence
of the JP2 clone of A. actinomycetemcomitans and
the initiation of attachment loss, suggesting the JP2 clone
to be an etiological factor of aggressive periodontitis
(33).
Continuously, it is an unanswered question if the JP2
clone-associated periodontitis is linked to a specific
genetic constitution and disposition of the North African
populations, for example, Berbers and Arabs. On the
other hand, several epidemiological studies reporting on
the disease prevalence of aggressive periodontitis among
the young in the United States have found a particularly
high prevalence of periodontal disease among black
Americans, but not reported on a particularly high
prevalence in populations originating from the Mediter-
ranean parts of Africa. However, determination of ethnic
origin may be difficult or even impossible due to lack of
information on the genetic origin of many groups of
humans. In particular, it may be a challenging task in a
continent like the United States, which has a long history
of ethnically mixed inhabitants (50). In the study on
periodontal epidemiology, carried out in 2010 in Sudan
by Elamin and coworkers (47), the study population was
selected in a multistage, stratified sampling design, and
ethnicity was categorized into Afro-Arab tribes and non-
Arab African tribes. In that study, a significantly higher
prevalence of aggressive periodontitis was found among
African tribes than Afro-Arab tribes (6% versus 2.3%,
p0.01) (47). Hence, this study also lends support of a
particularly high disease prevalence of periodontitis
among young black Africans.
In an attempt to further elucidate the topic on period-
ontal disease among black Africans and the colonization
with the JP2 clone of A. actinomycetemcomitans,w e
decided more recently to study aggressive periodontitis in
a sub-Saharan country. In 2008, when a study in Ghana
was designed and initiated, we found no West African
study on periodontal epidemiology that included micro-
biological analyses of A. actinomycetemcomitans, which
addressed the JP2 clone issue. Thus, no direct evidence for
thepresenceofthe JP2 clone of A. actinomycetemcomitans
in the sub-Saharan region of West Africa was available at
that point of time. However, case reports had indicated
that the JP2 clone of A. actinomycetemcomitans may be
present and implicated in the disease aetiology in that part
oftheAfricancontinent(63,85).Inaddition,somereports
on the periodontal conditions of West African adolescents
had been published, but those reports had focused onlyon
clinical aspects (52, 86). Many studies have reported black
Africans as particularly vulnerable to the development of
rapidly progressing and severe aggressive periodontitis,
but the studies did not include microbiological findings.
Therefore, we hypothesized that an endemic presence
of the JP2 clone of A. actinomycetemcomitans could be
implicated in the high prevalence and severe disease
manifestation in black Africans (34).
To generate more direct information on the conditions
in the sub-Saharan area of Africa, another prospective
cohort study was planned and carried out in Ghana
more recently. Five hundred Ghanaian school children
(mean age 13.2 years) were included in that prospective
cohort study (34). No exact information was available
Table 1 (Continued)
References
Number of subjects
in the study Country of residence
Number of subjects
positive for JP2
clone strains
Geographical origin
of subjects positive
for the JP2 clone
Bandhaya et al. (78) 453 Thailand 0 
Martinez-Martinez et al. (79) 75
e Mexico 0 
Wahasugui et al. (80) 113 Brazil 64 Not reported
Ho ¨glund A ˚ berg et al. (35) 397 Ghana 38 Ghanaian (38)
aThe study is based on A. actinomycetemcomitans (Aa) isolates and does not report on subjects.
b165 fresh Aa isolates from patients and 91 Aa strains previously collected from patients and non-human primates.
c21 Aa isolates of human origin and 14 Aa isolates from captive marmosets.
dAa isolates were detected from Brazilian Indians from the Umutina reservation, Mato Grosso, Brazil.
eAa isolates were obtained from patients with Down syndrome with or without periodontitis.
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the Ghanaian study was designed. However, all previous
periodontal studies on subjects of African descent had
indicated that the disease level in black Africans was
presumably high, and that suggested that a slightly
smaller sample size than in the Moroccan study would
be necessary in a study carried out in Ghana (33, 34).
At baseline, the Ghanaian cohort study showed that
there was a relatively high carrier rate of both JP2 and
non-JP2 genotypes of A. actinomycetemcomitans in the
Ghanaian adolescent population, and the overall carrier
rate of A. actinomycetemcomitans was 54.4%. Further-
more, the presence of this bacterium was associated with
the occurrence of periodontal attachment loss (34). The
highly leukotoxic JP2 clone was detected in 9%, and that
was comparable or slightly lower than the level found
previously in Morocco (32, 33). Thus, the JP2 clone is also
frequently found in the Ghanaian population. Further-
more, this study reported on some demographic, social
level, and oral hygiene factors. In individuals attending
public schools compared to those attending private
schools, more individuals were identified as carriers of
A. actinomycetemcomitans (63% versus 35%, respectively)
and periodontal attachment loss was more frequently
found (28.3% versus 5.8%, respectively) (34). In addition,
logistic regression analysis showed a significant associa-
tionbetweenthepresenceofA.actinomycetemcomitansand
no use of a tooth brush versus if a tooth brush was
used (p0.003). At baseline, the Ghanaian participants
(mean age 13.2 years) were young. Therefore, baseline
data according to the presence of non-JP2 and JP2
genotypes of A. actinomycetemcomitans and periodontal
status could not distinguish between the two possible
patterns of disease progression that might manifest at an
older age (33, 35).
Two years after baseline, follow-up data on the
Ghanaian adolescent population were collected (35).
Although many aspects, such as genetics, life style, living
condition, oral hygiene habit, food intake, and social
conditionwereverydifferentfromthelivingcircumstances
in Morocco, the overall results of the Ghanaian follow-up
study were in agreement with the results reported on the
Moroccan population (33, 35). Periodontally healthy
adolescents in Ghana who carried the JP2 genotypes of
A. actinomycetemcomitans at baseline had a significantly
increased risk (RR7.3; 95% CI [4.5, 11.9]) of develo-
ping attachment loss greater than or equal to 3 mm at
one or more periodontal sites over a 2-year period
compared with a reference group without detectable
A. actinomycetemcomitans. A less pronounced risk was
found in those individuals who carried the non-JP2
genotypes of A. actinomycetemcomitans (RR3.6; CI
95% [2.2, 6.0]) (35). Thus, the results from the prospective
cohort study performed in Ghana fully support the
previous findings in Morocco (3235, 81, 82).
Acquisition, stability, and transmission of the
JP2 clone of A. actinomycetemcomitans
It is well-known that a substantial proportion of human
populations worldwide are colonized with A. actino-
mycetemcomitans (31, 41, 87). By use of DNA-based
methods, it is not unusual to report that up to 6070%
of a group of individuals are positive for A. actinomy-
cetemcomitans. Hence, A. actinomycetemcomitans is a
bacterial species frequently found in dental plaque.
A. actinomycetemcomitans can be detected in the
oral cavity at an early age (31). It is also generally ac-
cepted that A. actinomycetemcomitans is vertically trans-
mitted from parent to child (29, 8897). Transmission of
A. actinomycetemcomitans between spouses has also been
reported (28, 98100). In addition, not family-related
horizontal transmission may occur, although it is more
difficult toshowdirectevidenceforit(101).Familystudies
are the most frequent study design for the demonstration
of transmission of microorganisms through close contacts
(29, 94).
Limitedinformationisavailableconcerningthestability
of A. actinomycetemcomitans. However, A. actinomy-
cetemcomitans appears to be a rather stable colonizer
with persistence for 16 years (determined by findings of
isolates of the same serotype twice) (102). Furthermore,
identical genotypes of A. actinomycetemcomitans (exam-
ined by AP-PCR and/or ribotyping) were repeatedly
detected in each of 52 subjects 0.511.5 years apart
(103). Therefore, it was concluded that spontaneous or
treatment-induced change of A. actinomycetemcomitans
strains appears to be extremely rare, and that colonization
with the same strain(s) seems to be remarkably persistent
(103). In contrast, other researchers have concluded that
A. actinomycetemcomitans, examined at the species level,
only appears to colonize transiently with random concor-
dance between results of the first and the second sampling
(104106). However, due to the extensive genetic diversity
of A. actinomycetemcomitans that is well-known today
(107), it is necessary to study the persistence of bacterial
isolates at the DNA level (clonal level), to be sure that it is
indeed an identical bacterial strain found at the follow-up.
Information on the acquisition, stability, and trans-
mission of the JP2 clone of A. actinomycetemcomitans is
scarce. It is known that the JP2 clone strains are present
at an early age. JP2 strains were detected in dizygote
twins at 7 years of age (95), and it has been reported that
the original donor of the JP2 strain was an 8-year-old
child with prepubertal periodontitis (108). Since the
clone is most likely acquired by vertical transmission
from parent to child, transmission of JP2 clone strains
probably occurs even before the ages mentioned above.
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the infection with JP2 clone strains [leukotoxic strains
according to Tsai and Taichman (5)] may exist, and that
the JP2 clone is more frequently found in children and
adolescents than in adults (60, 71). Haraszthy and
coworkers found a higher prevalence of highly leukotoxic
strains in children equal to or under the age of 14 years
than in subjects older than 14 years (81% versus 26%,
pB0.001) (60). In addition, longitudinal data on Moroccan
adolescents reports that few individuals are colonized
with the JP2 clone de novo after puberty (109). Thus, it is
likely that the JP2 clone preferentially infects younger
individuals. However, it cannot be completely excluded
that a disappearance of the clone in older individuals is
merely due to a decrease in the numerical level of the JP2
clone with increasing age. A decreased number of
bacteria would reduce the likelihood of capturing the
highly leukotoxic JP2 clone strains at the sampling
occasions, although JP2 clone strains are still present in
the oral cavity. An age predilection for JP2 clone infection
of only the young appears, however, to be in contrast
with more recent results obtained in Morocco (110). In
the Moroccan study by Ennibi and coworkers, it was
investigated if the JP2 clone was particularly linked to
the localized forms versus the generalized forms of aggres-
sive periodontitis (110). Among Moroccan patients seeking
periodontal treatment at the dental school in Rabat,
Morocco, it was found that localized as well as generalized
aggressive periodontitis patients were positive for the
JP2 clone of A. actinomycetemcomitans (83% versus 69%,
p0.17) (110). Since patients with generalized period-
ontitis are generally older than patients with localized
periodontitis, it appears that adults could be colonized
with the JP2 clone as well as children and adolescents,
but presumably it may be a less frequent event or that
the clone comprises a less dominating proportion of
the oral microbiota. Cortelli and coworkers also studied
periodontitis patients, positive for JP2 and non-JP2
genotypes of A. actinomycetemcomitans, in three different
age groups (1428, 2939, or 4076 years old) (71). The
JP2 clone strains were more prevalent among the younger
patients, whereas the non-JP2 genotypes were more
prevalent among the adult periodontitis patients (71).
Furthermore, a report on a Swedish family, surprisingly
without known ancestors from Africa (ancestry testing
was performed), recently showed that some of the family
members were positive for the JP2 clone of A. actinomy-
cetemcomitans. Two adult family members, a 33-year-old
daughter and her 62-year-old mother, were colonized
with the JP2 clone of A. actinomycetemcomitans. Thus,
the JP2 clone may be more prevalent among children
and adolescents, but apparently can also be detected in
adults (111).
The stability of JP2 and non-JP2 genotypes of
A. actinomycetemcomitans has also been studied in the
Moroccan population (109). Nearly half of the JP2 clone
carriers were persistently infected during the 2-year
follow-up period, which indicates a level of the stability
of the colonization with the JP2 clone similar to that
previously reported for the non-JP2 genotypes of
A. actinomycetemcomitans (103, 109, 112). However, the
relative risk for the development of aggressive periodontitis
was highest for individuals with stable JP2 clone coloni-
zation (33, 109). Although the method used (polymerase
chain reaction) in the first and the second Moroccan
cohort studies was not quantitative, these results add
to the evidence for a causal role of the JP2 clone in
aggressive periodontitis (109).
Studying the stability of JP2 and non-JP2 genotypes of
A. actinomycetemcomitans also revealed that a simulta-
neous occurrence of these genotypes appears to be an
unstable situation (109). The majority of the co-infected
Moroccan adolescents at baseline lost one of the clonal
types during the 2-year observation period. This outcome
might suggest a competitive exclusion between the differ-
ent A. actinomycetemcomitans genotypes. However,
the outcome of the competition is seemingly a stochastic
process, as either of the genotypes of A. actinomycetemco-
mitans appeared to take over with similar frequencies in
the age group studied. Thus, the fitness between the JP2
and non-JP2 clonal types of A. actinomycetemcomitans in
periodontal pockets seems to be similar (109).
Transmission of JP2 clone strains has been demon-
strated in several studies (29, 95, 111). As for other
genotypes of A. actinomycetemcomitans, the JP2 clone
is transmitted through close contacts. Thus, the JP2
clone does not seem to present another colonization
pattern than other genotypes of the species. Transmission
of the JP2 clone of A. actinomycetemcomitans within
families has been reported (29, 95), but the most exact
evidence of familial transmission of the JP2 clone has
been proven at the single nucleotide level (single muta-
tion) in a study on the microevolution of the JP2 clone of
A. actinomycetemcomitans (29). Thus, the colonization of
family members with JP2 clone strains with unique point
mutations provides the most exact and strongest evidence
that intrafamilial transmission of the JP2 clone of
A. actinomycetemcomitans occurs (29).
Geographical dissemination of the JP2 clone
of A. actinomycetemcomitans
Knowledge on human migration routes out of Africa and
worldwide spreading of the JP2 clone of A. acti-
nomycetemcomitans is of major interest to obtain further
insight into the epidemiology of the JP2 clone-associated
typeofperiodontitis.Althoughmappingofthegeographic
occurrence of the JP2 clone of A. actinomycetemcomitans
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is largely restricted to individuals of African descent, it is
still unknown how widespread in Africa the JP2 clone
of A. actinomycetemcomitans really is (Fig. 1). Character-
istic mutations allow JP2 clone isolates from the
Mediterranean area to be distinguished from isolates
from West Africa, including the Cape Verde islands. These
results suggest that the JP2 clone strains initially emerged
as a distinct genotype in the Mediterranean part of Africa
and subsequently spread to West Africa, and from there
they were transferred to the American continents during
the transatlantic slave trade (29). What is the situation
concerning potential spreading of the JP2 clone strains
to the Eastern parts of Africa? The JP2 genotype of
A. actinomycetemcomitanswas not found in a recent study
on adolescents, 1419 years old, living in Sudan (47) and
in a previous report, including isolates obtained from
subjects originating from Kenya, Tanzania, and Somalia
(30). Thus, the JP2 genotype of A. actinomycetemcomitans
is apparently more prevalent in the Northern and Western
parts of Africa than in countries in the Eastern part of
Africa. No report, which has studied the epidemiology
of the JP2 clone of A. actinomycetemcomitans in South
African populations, has been published.
In the middle of the 1990s, studies on the popula-
tion structure of A. actinomycetemcomitans led to the
conclusion that the highly leukotoxic JP2 clone of
A. actinomycetemcomitans apparentlyisabsentinNorthern
Europe (24). This finding created further interest in the
actual dissemination of the JP2 clone considered in a
worldwide perspective. Early reports from the 1980s
mentioned that strain JP2 was isolated from an 8-year-
old AfricanAmerican child with prepubertal peri-
odontitis (108). That strain was subsequently found to
have the characteristic 530-bp deletion in the promoter
region of the ltx operon and the strain belongs to the
JP2 clone. Information on the dissemination of the JP2
clone in a global perspective was not available at that
point of time.
Generous sharing of A. actinomycetemcomitans iso-
lates collected from individuals living in geographically
widespread areas and of different ethnic origin provided
an opportunity for studying the geographic dissemination
of the JP2 clone of A. actinomycetemcomitans (30). That
study, in which 38 out of 326 A. actinomycetemcomitans
strains collected turned out to be JP2 clone strains,
indicated a link to the African continent. Numerous
individuals from African countries (Algeria, Morocco,
Ghana, and the Cape Verde islands), among whom some
were recent immigrants to European countries, carried
the JP2 clone strains of A. actinomycetemcomitans (30).
In addition, a substantial number of strains collected
from black Americans were positive for the JP2 clone of
A. actinomycetemcomitans. Another interesting finding
was that individuals from countries previously colonized
by the Portuguese, for example, the Cape Verde islands
and Brazil, were positive for the JP2 clone (30). Alto-
gether, these findings led to the hypothesis that the JP2
clone of A. actinomycetemcomitans has emerged in the
African continent more than 2000 years ago, and since
then it has disseminatedworldwide through the migration
of African populations (29, 30).
A population genetic study attempted to elucidate
the genetic diversification of the JP2 clone at the
DNA sequence level by multilocus sequence typing.
The goal was to obtain information on the natural
history, origin, and global dissemination of the JP2
clone of A. actinomycetemcomitans. Although genetically
highly conserved, the study revealed that JP2 clone
strains have a number of point mutations, particularly
in the pseudogenes, hbpA and tbpA (29). Among a total
of 66 JP2 clone strains, 11 sequence types with minor
Fig. 1. (A) Illustration of the geographic area of Africa proposed to be the site of emergence (*) of the JP2 clone of
A. actinomycetemcomitans. After the characteristic mutational event, a 530-bp deletion in the promoter region of the leukotoxin
operon, the JP2 clone has disseminated to many parts of the world. (B) Dots illustrate the countries from where JP2 clone-
positive patients have been identiﬁed (as indicated in Table 1).
Dorte Haubek and Anders Johansson
8
(page number not for citation purpose)
Citation: Journal of Oral Microbiology 2014, 6: 23980 - http://dx.doi.org/10.3402/jom.v6.23980differences were identified. Such detailed studies on
specific point mutations revealed characteristic muta-
tions that allowed isolates from individuals from the
Mediterranean area and from West Africa, including the
Cape Verde islands, to be distinguished (29). The patterns
of mutations indicate, as previously mentioned that the
JP2 clone initially emerged in the Mediterranean part
of Africa and subsequently spread to West Africa, from
where it was transferred to the American continent
during the transatlantic slave trade. However, the entire
picture of the dissemination of the JP2 clone, even within
the African continent, is still not completely known.
Sporadic signs of the spreading of the JP2 clone to
Caucasians have been reported in the literature (60, 66,
111, 113). The proportion of individuals that are positive
for the JP2 clone is probably underestimated, because it
has only recently become clear that it is important to
know the exact subtype of A. actinomycetemcomitans that
the patients actually carry. Previously, microbiological
diagnostic testing was solely focused on if the patients
were positive or negative for A. actinomycetemcomitans at
the species level, and subtyping according to the leuko-
toxin promoter type was probably not done. Subtyping
according to the leukotoxin gene promoter type is a more
recent phenomenon. Recently, analyses of a collection
of A. actinomycetemcomitans strains from a microbio-
logical laboratory in Umea in Sweden surprisingly
showed that JP2 clone-positive individuals were occa-
sionally found among patients previously found to be
positive for A. actinomycetemcomitans at the species level.
Among 2529 A. actinomycetemcomitans strains obtained
from subgingival plaque samples, collected from 1084
patients during a 12-year period, the proportion of JP2
clone-positive patients was 2.6% [unpublished data,
abstract (58)]. Thus, JP2 clone strains seem to be more
widespread than initially believed, and they also seem
to be spread among individuals of non-African origin,
particularly in the Mediterranean part of the Middle
East. The mechanisms behind the dissemination of the
JP2 clone are not fully understood. Biologically as well
as socially-determined factors (a host tropism for parti-
cular populations and/or a tendency towards a social
separation of ethnically diverse population groups) might
be involved.
Methods for the detection of the JP2 clone
of A. actinomycetemcomitans
Methods for microbiological diagnostics have been avail-
able for years with the purpose to get information on the
composition of the oral microbiota in patients, and to
guide the clinicians in their choice of antimicrobial agent
in the periodontal treatment of patients (114). However,
clinicians have questioned, if microbiological diagnostic
testing provides any additional information that would
lead to different treatment approaches than if the clini-
cians did not have any information regarding the content
of the dental plaque collected from patients before the
initiation of the periodontal therapy. In the light of the
possibility for the presence of the JP2 clone of A.
actinomycetemcomitans, which is strongly associated with
disease progression (33, 35, 81), it might be valuable and
relevant information for clinicians treating periodontitis
patients to know about the JP2 clone infection profile.
For this purpose, it has been an aim of various studies
to develop techniques that can be used to obtain such
information.
PCR has been known for years and has been used to
detect A. actinomycetemcomitans at the species level. In
addition, a PCR specifically able to detect non-JP2 and
JP2 genotypes of A. actinomycetemcomitans was devel-
oped and was described in the early 2000s by Poulsen and
coworkers (115). More recently, Seki and coworkers
developed a new method, loop-mediated isothermal
amplification method (LAMP), for the identification of
JP2 clone-positive plaque samples (116). One of the
reported benefits of this method is the independency of
specialequipmentandtherebythatitcanbeusedinsettings
with no access to various types of PCR equipment.
In addition, the LAMP method is highly specific and
sensitive. The LAMP test was found to have a specifi-
city equivalent to and a sensitivity exceeding those
described for PCR methods. Concerning the sensitivity,
the detection limits for LAMP assay and PCR were
10 and 100 genome copies, respectively (116). Thus, the
LAMP reaction is easy to set up, is not time-consuming
to perform, and does not require special equipment.
This provides several advantages in clinical settings and
in population-based studies with limited access to labora-
tory technology (116). LAMP has been used by Elamin
and coworkers in a clinical study on Sudanese adoles-
cents (47). However, no patients in that study were posi-
tive for JP2 clone strains, neither by PCR nor by the
LAMP technique (47). The LAMP technique was also
used by Martinez-Martinez and coworkers to examine
plaque samples from Mexican periodontitis patients
with Down syndrome, but none of the patients in-
cluded in that study was positive for the JP2 clone of
A. actinomycetemcomitans (80).
Two studies have reported on real-time PCR developed
for the purpose of being able to quantitatively discrimi-
nate the highly leukotoxic JP2 clone strains from the
non-JP2 genotypes of A. actinomycetemcomitans in the
diagnosis of aggressive periodontitis (56, 117). So far
these methods have not been used in clinical studies.
Therefore, the real-time PCR method has not yet con-
tributed with results or conclusions on quantitative
aspects of the presence of JP2 and non-JP2 genotypes of
A. actinomycetemcomitans and the initiation and devel-
opment of periodontal attachment loss among the young.
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the JP2 clone of A. actinomycetemcomitans are available,
and can be used to generate information on the status of
the JP2 clone infection in parallel to other types of
periodontal intervention carried out concomitantly in
these periodontitis patients.
Exotoxins of A. actinomycetemcomitans
In the light of the overall topic of this review being par-
ticularlyvirulentclonaltypesofA.actinomycetemcomitans
and their association with periodontal disease, it cannot
be a surprise that attention is also given to updating
research on the exotoxins of A. actinomycetemcomitans.
Among many different virulence properties of A. acti-
nomycetemcomitans (for reviews see Refs. 6, 8, 21, 118
125), the two exotoxins, being leukotoxin (LtxA) and
cytolethal distending toxin (Cdt), have been intensely
studied over the years. Leukotoxin has been known for
the longest period of time, and it is of specific interest
for the virulence of the JP2 clone due to the high expres-
sion of leukotoxin from this genotype (31). In the follow-
ing, the two exotoxins of A. actinomycetemcomitans and
the most recent results within this field of research are
addressed.
Leukotoxin
Structure and function of leukotoxin
The ability of A. actinomycetemcomitans extracts to cause
death of leukocytes was initially reported more than
30 years ago (126, 127). A protein, named leukotoxin
(LtxA), was identified as the responsible molecule for the
leukotoxic effect that was restricted to human polymor-
phonuclear leukocytes (PMNs) andmonocytes (126128).
Later, itwasshown that LtxA can also affect lymphocytes,
erythrocytes, and endothelial cells from humans and
cells of animal origin. However, higher concentrations
of the toxin are needed than the concentrationswhich lyse
PMNs and monocytes (129133).
The A. actinomycetemcomitans LtxA operon consists
offourcodinggenesdesignatedltxC, ltxA,ltxB, andltxD,
and an upstream promoter (134). The gene, ltxA, encodes
for the structure of the toxin, ltxC encodes for compo-
nents required for posttranslational acylation of the toxin,
and ltxB and ltxD are involved in the activation and
transport of thetoxinto the bacterial outer membrane.
There is great variation in the leukotoxin expression in
vitro, although all A. actinomycetemcomitans strains
harbour a complete leukotoxin operon (6). Zambon and
coworkers showed that A.actinomycetemcomitans isolated
from periodontally diseased subjects showed significantly
enhanced leukotoxicity compared to isolates from peri-
odontally healthy subjects (135). Interestingly, certain
clones of the bacterium with enhanced leukotoxin expres-
sion have been shown to have a modified promoter in
the LtxA operon (28, 65). The most well-known phenom-
enon is the previously mentioned highly leukotoxic JP2
genotype of A. actinomycetemcomitans, characterised by
the 530-bp deletion in the promoter of the LtxA operon
(28, 31).
Leukotoxin is a large pore-forming protein that con-
sists of 1055 amino acids encoded by ltxA in the toxin
operon (134, 136). The molecule can be divided into four
regions based upon analysis of the amino acid sequence:
the N-terminal region, the central region, the repeat
region, and the C-terminal region (137). These four
regions in the molecule structure are shared among
many of the bacterial proteins in the RTX family (137,
138). The N-terminal region of LtxA, residues 1408,
exhibits alternating hydrophobic and hydrophilic clusters,
and the pore-forming region have been suggested to be
mediated by the hydrophobic clusters located between
residues 175400 (9, 18, 138). A cholesterol-binding site
(CARC336), necessary for an efficient binding to the
target cell membrane, has recently been demonstrated at
residues 333339 (139). The central region of the RTX
proteins at residues 409729 contains large hydrophilic
domains, and two acylation sites of LtxA are located at
lysine562 and lysine687 (140). The fatty acids at these
positions have been shown to be necessary for the activity
of the toxin and are suggested to contribute to the
anchorage at the target cell membrane (9, 140). The
repeat region of the RTX proteins consists of tandem
repeats of a cassette with nine amino acids located
between residues 730900, and 14 such repeats have
been identified in this region of LtxA (9, 18). The target
cell receptor lymphocyte function-associated antigen-1
(LFA-1) binds to the repeat region, and this interaction
has been shown to be responsible for the host cell
specificity of LtxA (19, 141). In addition, the glycine-
rich repeats in this region have strong capacity to bind
Ca
2, and the presence of these cations mediates
increased binding of the toxin to LtxA-sensitive LFA-1
expressing cells (142). Finally, residues 9011055 at the
C-terminal end of the RTX proteins have been shown to
be necessary for the export of the toxin to the bacterial
outer membrane by interactions with secretory proteins
(138). This region of LtxA contains 20 extra basic amino
acid residues in comparison with other RTX proteins and
this is the reason for its high isoelectric point (9.7) (134).
The expressed LtxA is transported to the bacterial
outer membrane by a type I secretion system (6, 143).
Whether the expressed and exported LtxA remains
associated with the bacterial outer membrane or is
secreted into the environment is a topic of controversy,
and the mechanisms that keep the toxin associated with
the membrane are still not fully understood. However, the
serum-mediated release of the toxin (144, 145), as well as
its highly systemic immunogenic response (146), indicate
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LtxA exhibits a unique specificity against cells of
haematopoetic origin from humans and some other
primates (19). This restricted host cell specificity suggests
that the species-specific effect of LtxA is mediated
through a unique receptor on the target cells (LFA-1),
and a distinct region in the toxin that recognizes and
interacts with the receptor (147, 148). The principal
feature of this species recognition region of LtxA is that
it contains a series of 14 tandemly repeated amino acid
sequences in the repeat region of the toxin (18, 142). The
domain of LtxA that recognizes the target cell receptor
has been shown to be residues 688941, examined by
epitope mapping with monoclonal antibodies (141).
The LFA-1 molecule, identified as the LtxA target cell
receptor, is a heterodimer consisting of the aL (CD11a)
and b2 (CD18) subunits. The residues 1128 on human
CD11a have been shown to be important for the human
specificity of LtxA-induced cell lysis (148). In addi-
tion, the extracellular region of human CD18 (residues
500600) has been shown to be critical for conferr-
ing susceptibility to LtxA-induced cell lysis (147, 149).
The most important host-related ligand of LFA-1 is
the intercellular adhesion molecule 1 (ICAM-1), but
this molecule binds to another region of the receptor
than the residues identified for the LtxA binding (147,
148, 150).
It has been suggested that the role of LFA-1 in LtxA-
mediated cell lysis is to help the protein to have a correct
orientation on the target cell membrane, which might
explain the enhanced sensitivity to LtxA in the LFA-1
expressing cells (9). Furthermore, the two fatty acids
strengthen the anchorage of the toxin when inserted in
the target cell membrane and the hydrophobic domain
forms small pores in the membrane. It has been suggested
that low concentrations of the toxin might induce
apoptosis through loss of membrane integrity caused by
the small pores, and that higher concentrations of the
toxin allow oligomerization of LtxA-LFA-1 complexes
on the target cell membrane, thus mediating a rapid and
complete membrane collapse (9). In addition, LtxA has
been shown to require lipid rafts for target cytotoxicity
and a specific cholesterol-binding site has recently been
identified on the LtxA molecule, which also indicates the
importance of a high mobility on the target cell mem-
brane (139, 151). The binding of LtxA to LFA-1 has been
shown to result in internalization to the lysosomal
compartment of the target cell (152).
The actual production of the toxin varies among
A. actinomycetemcomitans strains. One of several factors
that affect the toxin production is the presence of the
530-bp deletion in the promoter region of the leukotoxin
operon (28, 66). In the JP2 clone strains with the 530-bp
deletion, the leukotoxin production is reported to be 10
to 20-fold higher than in the non-JP2 genotypes of
A. actinomycetemcomitans (28, 153). This is supported
by recent transcriptomic analyses which show that the
expression of LtxA is enhanced in serotype b strains,
including the JP2 genotype (154). In addition, the
expression of leukotoxin is reported to be regulated by
other genetic and environmental factors (15, 155158).
Host response to leukotoxin
Leukotoxininteractswithdifferenthostcellsinavarietyof
ways that activate cellular and molecular mechanisms,
some of which are associated with the pathogenesis of
periodontitis. Taken together, themany virulence mechan-
isms of LtxA described below indicate an important
role of this toxin in A. actinomycetemcomitans-induced
periodontal breakdown, specifically for the JP2 geno-
type-associated periodontitis. However, it is still not fully
known if other highly leukotoxic clones of A. actinomy-
cetemcomitans besides the JP2 clone might have a sig-
nificant association with disease progression (28, 65).
Polymorphonuclear leukocytes
LtxA and leukotoxic bacteria have been shown to effi-
ciently cause death of human PMNs, and consequently
LtxA is assumed to protect A.actinomycetemcomitans
against phagocytic killing (6). Furthermore, analyses of
PMNs exposed to leukotoxin have shown an extracellular
release of proteolytic enzymes from both primary and
secondary granules (11). Moreover, the interaction be-
tween LtxA and PMNs mediates activation and release of
matrix metalloproteinase 8 (159). Taken together, these
findings indicate that beyond causing death of the PMNs,
LtxA also induces activation and release of proteolytic
enzymes from these cells, which might contribute to the
disease progression. Impaired PMN function is closely
associated with periodontitis, and functional PMNs seem
to be of importance when A. actinomycetemcomitans is
present in the subgingival biofilm (160163).
Lymphocytes
Lymphocytes were initially described as LtxA-resistant
cells (126, 127). The first observation of LtxA-susceptible
cells of lymphocytic origin was made by Simpson and
coworkers (164) who showed that several lymphoid cell
lines were killed in the presence of LtxA. In addition,
LtxA was shown to suppress the function of peripheral
blood lymphocytes (165). A few years later, Mangan and
coworkers showed that T-cells isolated from human
peripheral blood were affected by LtxA (129). This
LtxA-induced T-cell death was a slow process compared
to that which lysed human cells of myeloid origin and the
cell death was shown to be induced through apoptosis
(129). It has also been shown that the human natural
killer (NK) cells are affected in a similar way by LtxA as
the T-cells are, while the effects of LtxA on human B-cells
or plasma cells have not been specifically addressed (165).
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Human lymphocytes show a great heterogeneity in
regard to LtxA sensitivity and a subgroup of these cells
has been shown to be lysed at approximately the same
concentrations as human PMNs (130). Cells of lymphoid
origin are rare in the infected periodontal pocket, but
reside in high numbers in the surrounding tissues and in
the lymph glands (166). It was shown more than 30 years
agothat the onset of periodontitis involvesa switch from a
T-cell lesion to one involving large numbers of B-cells and
plasma cells (166). A shift occurs in the balance between
the so-called Th1 and Th2 subsets of T-cellswith Th2 cells
being associated with chronic periodontitis (167). More
recently, T-regulatory (Treg) and Th17 cells have been
detected in periodontal tissues indicating that these cells
are also important in the host response and pathogenesis
of periodontal disease (168). The strong acquired systemic
humoral immune response induced by LtxA indicates
directcontact betweenthis molecule and cells of lymphoid
origin (146, 169). The ability of LtxA to induce apoptosis
in lymphocytes might contribute to a locally impaired
acquired immune response in periodontal infections. The
ability of LtxA to also affect lymphocytes indicates a
possible role of this molecule in Th1/Th2/Th17 differ-
entiation, a process that seems to be of great importance
in the pathogenesis of inflammatory diseases, such as
periodontitis (168).
Monocytes/macrophages
Previously, it was shown that human monocytes are
sensitive targets for LtxA, and it has been described that
the sensitivity of these subsets of leukocytes is at a similar
level as for human PMNs (126). Characterisation of the
LtxA-induced monocyte killing has been described in
three different phases: (1) cessation of the membrane
undulating folding and an accumulation of granulae in
the perinuclear area; (2) abnormal membrane movement
and strings of cytoplasm projecting from the cell; and (3)
explosive release of cytoplasmic material from the cell
(128). However, it should be taken into consideration that
this study was made with ‘crude LtxA extract’ that
contained a large number of other bacterial components.
Rabie and coworkers showed that purified LtxA caused a
rapid death of human monocytes in mixtures of the toxin
with peripheral blood mononuclear leukocytes (MNLs)
(165). More recently, analyses of different subsets of
leukocytes separated from peripheral blood of a single
donor showed that monocytes have an enhanced sensi-
tivity to LtxA compared with PMNs and lymphocytes
(130). The LtxA-induced monocyte lysis was shown
to involve activation of caspase-1, which indicates in-
volvement of pro-inflammatory intracellular signalling
(Fig. 2). Caspase-1 is a cytosolic cysteine proteinase that
specifically induces activation and secretion of the pro-
inflammatory cytokines interleukin-1b (IL-1b) and inter-
leukin-18 (IL-18) (170). Both of these pro-inflammatory
cytokines are expressed as biologically inactive precursors
and have to be cleaved by caspase-1 for activation and
secretion. Caspase-1 is activated by incorporation in a
cytosolic multimer complex named the inflammasome
(171). The intracellular signalling pathways involved in
LtxA-induced inflammasome activation in human mono-
cytes/macrophages have not yet been determined. A
partial characterisation of this process indicates involve-
ments of K
 efflux and ATP release that might activate
purogenic receptors, such as the P2X7 (172).
The observation that LtxA induces activation of
caspase-1 in human inflammatory defence cells indicates
a new role for this virulence factor as a mediator of the
pro-inflammatory host response. Human macrophages
(adherent blood monocytes), exposed to LtxA, activate
a rapid and abundant secretion of bioactive IL-1b
(173). Moreover, exposure of human macrophages to
components of Gram-negative oral pathogens causes
an increased accumulation of cytosolic pro-IL-1b and
inflammasome molecules that is not activated and
released (reformulate) (174, 175). LtxA or leukotoxic
A. actinomycetemcomitans induces cleavage and secretion
of these accumulated pro-inflammatory molecules, a
property that is abolished in A. actinomycetemcomitans
mutants without LtxA expression (174). The IL-1b secre-
tion is activated already at a concentration of one
bacterium/macrophage in interactions with bacteria from
the highly leukotoxic JP2 genotype of A. actinomy-
cetemcomitans and with a similar activation by non-JP2
genotype strains, however, at a 10-fold higher concen-
tration (174). Taken together, these data show that LtxA
is the major component of A. actinomycetemcomitans
for the induction of the activation and release of IL-1b
from human macrophages, and that this effect is further
enhanced by priming of the macrophages with other
bacterial components.
Macrophages are rare cells in a healthy periodontium,
but they are often found in high numbers in tissues from
periodontal lesions (166). These cells are recruited to the
infected site from the peripheral blood monocytes that
are attracted by ICAM-1-expressing endothelial cells.
The monocytes pass through the vessel wall and migrate
towards a gradient of compounds in the connective tissue
that are released from the oral biofilm and the activated
host cells (176). During diapedesis, the monocytes
differentiate into macrophages and the inflammatory
machinery is up-regulated during this process and further
during the migration towards the infected site. This
process involves an accumulation of pro-inflammatory
precursor molecules, such as IL-1b and IL-18 in the
migrating macrophages (170). A secondary stimulus is
needed to induce activation and release of the accumu-
lated precursors of IL-1b and IL-18 in the primed
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ing A.actinomycetemcomitans, the gradient of bioactive
components in the connective tissue will contain LtxA,
and the migrating macrophages will sooner or later meet
concentrations of LtxA that activates secretion of these
pro-inflammatory cytokines into the surrounding tissues.
If this process is activated in the tooth-supporting tissues
in the vicinity of the infection, it might cause imba-
lance in the host inflammatory response and promote
pathogenic cellular mechanisms (Fig. 3, modified from
Ref. 177).
The highly systemic immunogenic host response
against LtxA of A. actinomycetemcomitans-infected sub-
jects indicates that direct contact between the antigen-
presenting macrophages and LtxA occurs (146, 169).
The enhanced LtxA sensitivity of human macrophages
indicates that these antigen-presenting cells might be
affected during a primary infection with leukotoxic
A. actinomycetemcomitans, which might cause a delayed
acquired immune response.
Erythrocytes
The ability of some strains of A. actinomycetemcomitans
to cause b-haemolysis on blood agar plates has been
known for many years (27, 30, 178). It was later reported
that the haemolysis of red blood cells of human and
animal origin that is caused by A. actinomycetemcomitans
involves interaction with LtxA (22, 131). Different strains
of the bacterium with varying expression levels of
LtxA show specific patterns when cultured on blood
agar plates containing fresh horse blood. Red blood cells
lack the expression of the LtxA receptor, LFA-1, which
has been shown to be a prerequisite for the LtxA-induced
leukocyte lysis (141). The cellular and molecular mecha-
nisms for this haemolytic effect of LtxA are therefore not
fully understood. It has recently been shown that LtxA-
induced haemolysis involves interaction with the P2X7R
(P2X purinoceptor 7, an ATP-gated ion channel) on
the surface of the red blood cells (179). In addition, the
extracellular release of ATP is mediated through a pore
formed by the toxin (180). Whether this haemolytic
property of LtxA is a virulence mechanism is still not
known.
Endothelial cells
LtxA has recently been shown to induce a substantial pro-
inflammatory effect on human brain endothelial cells by
up-regulation of ICAM-1 and VCAM-1 (132). Further-
more, a higher concentration of LtxA was found to
decrease proliferation and induce apoptosis in microvas-
cular endothelial cells. The involvement in the pathogen-
esisofperiodontitisbythesemechanismsisnotknown,but
the endothelial cells may play a role as a link between
periodontitis and cardiovascular diseases.
Fig. 2. A. actinomycetemcomitans with its leukotoxin is a useful tool to study important virulence mechanisms for the
progression of periodontitis.
This bacterium has a strong association with aggressive forms of periodontitis, and the leukotoxin may represent a major
virulence factor. We have identiﬁed several cellular activation pathways that are induced upon exposure to leukotoxin
(Ref. 12). Brieﬂy, leukotoxin binds to the LFA-receptor (1) and activates an extracellular release of ATP (2), which acts as a
ligand for the P2X7-recptor, and results in an efﬂux of potassium (3). These events activate the formation of an inﬂammasome
multimer (4) that activates the cysteine proteinase caspase-1, resulting in activation (5), and a massive secretion of IL-1b (6).
This pro-inﬂammatory cytokine is a key molecule that regulates the balance between catabolic and anabolic processes in
tissue homeostasis, and therefore is of speciﬁc interest for tissue degenerative diseases, such as periodontitis (modiﬁed from
Ref. 177).
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The cytolethal distending toxin (Cdt) is a highly con-
served exotoxin produced by a number of Gram-negative
bacteria (181). It affects mammalian cells by inhibiting
cell division and by causing apoptosis (182). The active
holo-toxin is a heterotrimeric complex of CdtA, CdtB,
and CdtC. CdtA and CdtC are necessary for the
secretion of the toxin, while CdtB is responsible for the
biological activity (183). CdtB has a sequence homology
with mammalian DNaseI, indicating a critical role for
nuclease activity in host parasite interactions (184).
Apart from blocking cell cycle progression, Cdt also
induces expression of the receptor activator of NF-
kappaB ligand (RANKL) in human periodontal fibro-
blasts and lymphocytes (185, 186). RANKL is a key
cytokine for bone resorption and could therefore be
associated with the pathogenic mechanisms of period-
ontitis (187). In addition, Cdt affects the oral epithelium
ex vivo and therefore might contribute to impair
the barrier function of epithelial cell layers against
invading microorganisms (188, 189). Initially, the Cdt
was discovered in A. actinomycetemcomitans by Sugai
and coworkers (190). However, already in the 1980s and
the beginning of the 1990s, several studies reported on
the inhibition of cell proliferation, cell cycle-specific
growth inhibitory effect, and immunosuppression induced
by A. actinomycetemcomitans (191194).
Of interest in relation to periodontitis, it is known that
Cdt resides in the variable region of the pangenome, and
consequently it is not present in all A. actinomy-
cetemcomitans strains (107). However, the genes are
present in the majority of the isolated A. actinomy-
cetemcomitans, including the JP2 clone strains, but the
proportion of isolates that lack all or some of the genes
varies among the populations studied (25, 72, 195201).
The systemic immunoreactivity to Cdt has also been
studied and assumed to be a marker for the presence of
Cdt-expressing A. actinomycetemcomitans (202, 203).
Interestingly, while all carriers of A. actinomycetemco-
mitans exhibit neutralizing antibodies to LtxA (146), the
systemic immunoreactivity to Cdt is not always able to
neutralize the toxin (202, 203). Thus, Cdt can sometimes
act as a virulence factor that is not neutralized by an
acquired humoral immune response.
Despite substantial evidence supporting the fact that
Cdt can function as a virulence factor of pathogens
producing the toxin (181), the importance of Cdt in the
pathogenesis of periodontal disease seems to be limited.
This topic was addressed in a recent longitudinal study
based on 500 Ghanaian adolescents (201). In that study,
Fig. 3. Bacterial bioﬁlm, containing a high proportion of highly leukotoxic A. actinomycetemcomitans (JP2 clone strains), can
be assumed to release leukotoxin that activates the immune cells in the periodontal pocket and the surrounding tissues.
Leukotoxin has been shown to induce degranulation of PMNs and a pro-inﬂammatory response in macrophages. This results in
the release of biologically active molecules with a capacity to cause an imbalance of the host response that can promote
degenerative processes in the tooth-supporting tissues (modiﬁed from Ref. 177).
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with the presence of A. actinomycetemcomitans, and
progression of the periodontal attachment loss was only
weakly associated with the cdt-genotype of the bacterium
(201).
Treatment of JP2 clone-associated aggressive
periodontitis
As mentioned above, A. actinomycetemcomitans has
numerous important virulence properties (6, 8, 21), and
the bacterium is considered as a periodontal pathogen.
For decades, clinicians and researchers have been aware
of the potential role of A. actinomycetemcomitans in
periodontal disease and particularly its association with
disease in adolescents. This focus has been intensified
in light of the reporting of particularly virulent clones
of A. actinomycetemcomitans and their strong association
with disease. Although reports on the treatment of JP2
clone-associated periodontitis are limited, this topic will
be touched on below as a part of the translational
research line addressed in the present review.
Very limited information is available concerning ther-
apeutic aspects of the JP2 clone-associated periodontitis.
One report has addressed the topic directly and has
focused on the response to periodontal treatment in
subjects infected with either JP2 or non-JP2 genotypes
of A. actinomycetemcomitans (204). The use of antibiotics
as a supplement to conventional periodontal therapy
has also been studied by Cortelli and coworkers (204).
A total of 25 JP2 clone genotype-positive subjects and
25 non-JP2 genotype-positive subjects were included, and
participants received scaling and root planning, systemic
antibiotic therapy, and periodontal surgery during the
first 4 months of the study. The administration of systemic
antibiotics (prescription of 21 tablets of metronidazole
at 250 mg plus amoxicillin at 500 mg, one tablet every
8 hours for 7 days) was conducted in combination with
mechanical debridement in the second month of the study
period. In that study, probing pockets depths, clinical
attachment level and gingival and plaque indices were
monitored at baseline and at a 1-year follow-up, along
with PCR-based detection for the presence of JP2 and
non-JP2 genotypes of A. actinomycetemcomitans. The
overall conclusion of the study was that patients infected
with JP2 clone strains showed less response to the
periodontal therapies than did subjects infected with the
non-JP2 genotypes of A. actinomycetemcomitans (204).
Surprisingly, more than half of the subjects remained
positive for the JP2 clone strains, even after the intensive
treatment employed in the study. This made the authors
conclude that establishment of a more effective therapy
that can eliminate highly leukotoxic clones of A. acti-
nomycetemcomitans is required (204). Concerning the use
of antibiotics in the treatment of JP2 clone-associated
aggressive periodontitis, it is worth mentioning that
the potential problems related to antibiotic resistance
may varyin different countries. Sanz and coworkers found
a variation in the composition of the subgingival micro-
biota of two periodontitis populations of different
geographical origin. Thirty-one adult periodontitis pa-
tients from Spain and 30 comparable patients from
The Netherlands were included in the study (205). A. acti-
nomycetemcomitans was significantly more prevalent
(23.3% vs. 3.2%) in the Dutch group, while Porphy-
romonas gingivalis was significantly more prevalent
(64.5% vs. 36.7%) in the Spanish group. Thus, the
subgingival microbiota from the Spanish group was
characterised by a high prevalence of P. gingivalis and
low prevalence of A. actinomycetemcomitans, while the
microbiota from the Dutch group was characterised by
a high prevalence of both A. actinomycetemcomitans
and Peptostreptococcus micros (205). In addition, the
antimicrobial susceptibility profiles of five periodontal
bacterialspecies, beingA.actinomycetemcomitans, Porphy-
romonas gingivalis, Prevotella intermedia, Fusobacterium
nucleatum, and Micromonas micros, isolated from period-
ontitis patients in Spain and in The Netherlands were
analysed (206). Eight different antibiotics were tested on
all the bacterial isolates, and it was concluded that
differences exist in the susceptibility profiles of the period-
ontal pathogens isolated from periodontitis patients in
Spain and in The Netherlands. This indicates that
antibiotic susceptibility testing is necessary to determine
efficacy of antimicrobial agents (206). Furthermore,
the findings from the study indicate that it may not be
possible to develop uniform protocols for the usage of
antibiotics in the treatment of periodontitis (206). More
recently, a study concluded that A. actinomycetemcomi-
tans JP2 homotypic biofilmswere more susceptible invitro
to doxycycline than amoxicillin plus metronidazole (207),
which is ‘the cocktail’of antibiotics usually recommen-
ded in aggressive periodontitis patients (208214). The
scenario concerning resistance to various antibiotics has
not been addressed in relation to the treatment of the
JP2 clone-associated periodontitis, for example, in studies
carried out in Northwest African countries. Thus, in the
Northwest African countries treatment outcomes of JP2
clone-associated periodontitis, including the use of anti-
biotics are unknown at present.
Conclusions and future perspectives
Accumulating knowledge at the genome level, including
rather detailed information on specific virulence factors,
and information from transcriptomic and proteomic
analyses of A. actinomycetemcomitans strains are avail-
able today (215218). These provide an excellent plat-
form for more studies on the details of the patho-
genic mechanisms of A. actinomycetemcomitans in the
future.
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studied is the highly leukotoxic JP2 clone of A. actino-
mycetemcomitans. Strong evidence exists for the role
of the JP2 clone of A. actinomycetemcomitans as an
aetiological factor in the pathogenesis of aggressive
periodontitis in certain populations. However, it is still
not clear if the link to the Northwest African populations
is related to a particular host tropism or to a ‘slow’
geographic dissemination of the JP2 clone. A ‘slow’
dissemination of the JP2 clone could occur due to a
number of factors that affect the ability of the disease
to manifest itself under various conditions in human
beings.Thesefactorsmayincludethegeneralhealthstatus,
living circumstances, social behaviour, level of knowledge
concerningpossibilitiesforthepreventionofperiodontitis,
and access to dental care. In addition, humans some-
times migrate from one country to another or from one
continent to another, but they still tend to cluster with
other humans with a similar ethnic origin, and that could
diminish the likelihood of the spreading of the JP2 clone.
Although the dissemination of the JP2 clone is more
widespread than initially anticipated, the spreading of the
clone does not seem to occur easily, as seen in the light of
the estimated time of its emergence in the Mediterranean
part of Africa more than 2000 years ago (29).
While the leukotoxicity of JP2 clone strains of
A. actinomycetemcomitans has been studied and reported
on, it is still not clear if other highly leukotoxic clonal
types of A. actinomycetemcomitans exist. One report from
Japan has reported on an A. actinomycetemcomitans
isolate with an insertion in the leukotoxin operon and
with an increased leukotoxicity (65). In addition, A ˚ berg
and coworkers have contributed with further information
on the leukotoxic activity of A. actinomycetemcomitans
strains (219). This study supports an important role
of the leukotoxin in the pathogenesis of aggressive
periodontitis. Concerning the Cdt, it has been shown
that presence of A. actinomycetemcomitans with or with-
out Cdt activity has similar importance for the disease
progression, indicating a less important role of this
exotoxin (201).
Whereas several techniques havebeen developed that aim
to detect A. actinomycetemcomitans, including specifically
the JP2 clone strains (56, 115117), limited information
concerning strategies for the treatment of the JP2 clone-
associated periodontitis has been reported (204).
A future preventive strategy for aggressive period-
ontitis might be modulation or blocking of virulence
potential. Recently, we have found that an extract from
the tropical plant, Psidium guajava, efficiently neutralizes
the A. actinomycetemcomitans leukotoxin (220). This
knowledge might contribute to the development of new
preventive strategies in the future, strategies that may also
be available for individuals in the developing countries.
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